Alphamab Oncology, a Suzhou, China-based clinical-stage biopharmaceutical company, raised more than $100m series A financing.
Backers included Advantech Capital, PAG, China Venture Capital Fund, OrbiMed, Heritage Provider Network and Janchor Partners.
The company plans to use the funds to advance global clinical development of its pipeline, especially its second-generation immuno-oncology medicine, to expand its global clinical and commercial teams, as well as to complete the ongoing construction of its biologics manufacturing facilities.
Led by Dr. Xu Ting, Chairman and CEO, Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of innovative therapeutics for cancer treatment. With multiple in-house proprietary platforms, including bispecifics, protein engineering and antibody screening, the company has built an oncology/immunology pipeline including:
– KN035 (Envafolimab), a subcutaneously-administered PD-L1antibody, which has entered pivotal trials in China and is expanding its indications.
– KN046, a PD-L1 – CTLA-4 bispecific antibody which, developed internally, is in phase I clinical trial in Australia, and will soon kick off multiple phase I/II clinical trials in China, with BLA enabling trials planned as well.
– KN026, an anti-HER2 bispecific antibody, which has entered phase I clinical trial in China.